Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.15)
# 456
Out of 4,944 analysts
65
Total ratings
52.17%
Success rate
15.12%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $67.52 | +12.56% | 4 | Aug 7, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $10 → $14 | $12.66 | +10.58% | 5 | Aug 6, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $12.66 | +10.58% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $32.46 | -4.50% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $12.81 | -29.74% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $27.45 | +20.22% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $121.40 | +56.51% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $88.00 | +13.64% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.89 | -9.05% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $285.52 | +36.59% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $66.34 | -17.09% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $55.10 | -0.18% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $117.32 | +36.38% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $477.41 | +40.34% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $6.03 | +231.67% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,292.89 | +8.28% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.21 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $32.36 | +178.12% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $205.72 | +31.25% | 4 | Dec 20, 2023 |
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $67.52
Upside: +12.56%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10 → $14
Current: $12.66
Upside: +10.58%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $12.66
Upside: +10.58%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $32.46
Upside: -4.50%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $12.81
Upside: -29.74%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $27.45
Upside: +20.22%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $121.40
Upside: +56.51%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $88.00
Upside: +13.64%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.89
Upside: -9.05%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $285.52
Upside: +36.59%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $66.34
Upside: -17.09%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $55.10
Upside: -0.18%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $117.32
Upside: +36.38%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $477.41
Upside: +40.34%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $6.03
Upside: +231.67%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,292.89
Upside: +8.28%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $32.36
Upside: +178.12%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $205.72
Upside: +31.25%